ey0016.8-10 | Clinical Trials - New Treatments | ESPEYB16
B Trinh
, M Hepprich
, MJ Betz
, T Burkard
, C Cavelti-Weder
, E Seelig
, F Meienberg
, DV Kratschmar
, F Beuschlein
, M Reincke
, A Odermatt
, MN Hall
, MY Donath
, MM Swierczynska
To read the full abstract: J Clin Endocrinol Metab. 2019; pii: jc.201900563.Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, affecting ~6% of the adult general hypertensive population. Patients with PA are at increased risk of cerebrovascular and cardiovascular morbidity, renal abnormalities and metabolic syndrome. The activity of mTORC1 ...